NetMHCIIphosPan: A Machine Learning Tool for Predicting HLA Class II Antigen Presentation of Phosphorylated Peptides
Clinical Snapshot
PICO Framework
| P — Population | Mass spectrometry-based immunopeptidomics datasets containing HLA class II phosphorylated peptides |
| I — Intervention | NetMHCIIphosPan machine learning prediction tool |
| C — Comparator | Existing prediction tools (NetMHCIIpan-4.3 and MixMHC2pred-1.3) |
| O — Outcomes | Predictive accuracy for HLA class II antigen presentation of phosphorylated peptides |
Bottom Line
NetMHCIIphosPan represents a significant advancement in predicting HLA class II presentation of phosphorylated peptides, addressing a critical gap in immunoinformatics. The tool demonstrates superior performance compared to existing methods by incorporating refined mass spectrometry data and both modified and unmodified peptides in training. While the computational approach is sound and the potential applications in immunotherapy and vaccine design are substantial, the abstract lacks detailed performance metrics and statistical validation. The tool's utility for Australian researchers in cancer immunotherapy and vaccine development is considerable, though clinical translation will require extensive validation. Clinicians should view this as a promising research tool rather than a clinical decision-making instrument at this stage. The work advances our understanding of the HLA-II phospholigandome, which is crucial for developing next-generation immunotherapies targeting post-translational modifications in disease-associated proteins.
Key Findings
P Value: Not reported
Effect Size: Not specified in abstract
Primary Outcome: Superior predictive performance compared to existing tools for HLA class II phosphorylated peptide presentation
Nnt Or Sensitivity: Sensitivity and specificity metrics not provided in abstract
Confidence Interval: Not provided
Clinical Application
High - computational tool that can be readily implemented in research settings Highly relevant for Australian immunology research groups, cancer immunotherapy programs, and vaccine development initiatives. Could support TGA regulatory submissions for novel immunotherapies Researchers and clinicians working in immunotherapy, vaccine development, and autoimmune disease research
Abstract
Phosphorylated peptides presented by human leukocyte antigen (HLA) class II molecules play pivotal roles in immune regulation, yet their characterization and prediction remain challenging due to data noise and limited HLA coverage. Here, we introduce NetMHCIIphosPan, a prediction method for HLA-II antigen presentation of phosphorylated peptides, developed using mass spectrometry (MS)-based immunopeptidomics data sets. Employing a refined peptide identification workflow, we reanalyzed earlier HLA-II phospholigand data sets and trained predictive models, achieving superior performance compared to models trained on the original data. Binding motif analysis revealed that HLA-specific preferences for phospholigands closely aligned with those of unmodified ligands. Incorporating unmodified ligands into training further enhanced predictive accuracy, particularly for HLA-DP and HLA-DQ molecules. NetMHCIIphosPan outperformed existing tools, such as NetMHCIIpan-4.3 and MixMHC2pred-1.3, for prediction of HLA antigen presentation of phosphorylated peptides, demonstrating robustness and utility. This work establishes NetMHCIIphosPan as a state-of-the-art tool for understanding the HLA-II phospholigandome, with potential applications in immunotherapy and vaccine design.
References
- 1.Garcia Alvarez, H. M., Kaabinejadian, S., Yari, H., Shepherd, C. M., Hildebrand, W. H., Sette, A., Peters, B., Parker, R., Ternette, N., & Nielsen, M. (2026). NetMHCIIphosPan: A machine learning tool for predicting HLA class II antigen presentation of phosphorylated peptides. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.5c01284
Related Research
Rheumatic diseases clinics of North America
Toward Artificial Intelligence-driven Clinical Decision Support Tools in Rheumatology
1 Aug 2026
Proceedings of the National Academy of Sciences of the United States of America
Magnetically actuated microrobotic system for sequential treatment of biofilm
15 July 2026
Journal of neurology
The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review
5 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service